287
Participants
Start Date
March 29, 2017
Primary Completion Date
September 30, 2026
Study Completion Date
December 31, 2026
NaBen®
2000 mg/day or 1000 mg/day, twice daily
Placebo
0 mg total, twice daily
RECRUITING
For additional information regarding investigative sites for this trial, contact SyneuRx International Corp., Pasadena
Collaborators (1)
Amarex Clinical Research
OTHER
SyneuRx International (Taiwan) Corp
INDUSTRY